Genmab ponders next steps after preliminary cancer candidate results

Genmab and partner Abbvie are ready to confer with global health authorities about planning the next steps for their cancer drug.

Photo: Joost Melis / Genmab / PR

Biotech firm Genmab and partner Abbvie have reported topline results from a phase I/II study of candidate epcoritamab, a subcutaneous drug against large B-cell lymphoma (LBCL), the companies have announced in a joint press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs